Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 149

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 149
---
 global sales milestones.

Other than the proceeding
mentioned above, we are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business
face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including
intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these
claims could subject us to costly litigation and, while we generally believe that we have adequate insurance to cover many different
types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy
limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could
have a material adverse effect on our operations, cash flows and financial position. Additionally, any such claims, whether or not successful,
could damage our reputation and business.

<div align='center'>90

MANAGEMENT</div>

Executive Officers and Directors

The following table sets
forth information regarding our executive officers and directors, including their ages as of the date of this prospectus:

| Name                    |     | Age |     | Position                |
| Dr. Ehud Geller         |     |  78 |     | Director, Chairman      |
| Mr. Jeff Dykan          |     |  65 |     | Director                |
| Mr. Keith Valentine     |     |  56 |     | Director(1)             |
| Dr. Eli Hazum           |     |  76 |     | Chief Executive Officer |
| Mr. Arie ‌ Gordashnikov |     |  42 |     | Chief Financial Officer |
| Efraim Cohen-Arazi      |     |  68 |     | Director Nominee(1)     |
| Mr. Pini Ben-Elazar     |     |  52 |     | Director Nominee(1)(2)  |
| Dr. Susan Alpert        |     |  76 |     | Director Nominee(1)(2)  |

| (1) | Indicates an Independent                                                 
 Director and a member of our Audit Committee and Compensation Committee. |

| (2) | Each of Mr. Ben-Elazar                                                                                                               
 and Dr. Alpert will become a director at the effective time of the registration statement to which this prospectus relates, and will 
 serve as an